Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 6 · 85.7%Moderate 1 · 14.3%High 0 · 0%

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in pulmonary exacerbations: number of pulmonary exacerbations compared with tobramycin (moderate certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 1.19 [0.86, 1.64]
1 study · 374 participants
Moderate

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

QoL · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Survival: number of deaths · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in survival: number of deaths compared with tobramycin (low certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 0.21 [0.01, 4.32]
1 study · 374 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Antibiotic resistance: change in mean MIC50 and MIC90 at the end of the trial · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Adverse events: number of treatment related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: colistimethate dry powder for inhalation… may leads to higher adverse events: number of treatment related adverse events compared with tobramycin (low certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 1.76 [1.5, 2.08]
1 study · 379 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low